The global influenza vaccine market, valued at $8.96 billion in 2024, is projected to reach $13.32 billion by 2030 with a 7% annual growth rate. Growth is fueled by rising public health awareness, an expanding elderly population, government immunization programs, and ongoing vaccine research. Innovations in vaccine technology, including cell-based and mRNA vaccines, along with increased accessibility through public campaigns, are key drivers. North America leads the market, while Asia Pacific is expected to grow fastest, supported by large populations and improved healthcare infrastructure.
GSK's hepatitis B treatment, Hibsago (bepirovirsen), received FDA approval for adults with chronic hepatitis B without cirrhosis, supporting Jefferies' forecast of peak annual sales at £2.2 billion. The drug offers a potential functional cure, allowi...
HUTCHMED has finalized an exclusive license agreement with GSK granting GSK rights to develop and commercialize HMPL-A830, a novel KRAS-EGFR antibody conjugate therapy, outside China, Hong Kong, Macau, and Taiwan. This therapy targets cancers with KR...
The FDA has approved Jemperli (dostarlimab) as the first immunotherapy for adults with stage II and III MSI-H/dMMR locally advanced rectal cancer. This approval is based on the AZUR-1 trial showing 68% of patients achieved complete clinical response ...
Jefferies has upgraded GSK PLC to a 'buy' rating with a 2,500p price target, suggesting a 34% gain from recent levels. This follows positive results from the EMBOLD trial of GSK's experimental lung cancer drug ris-rez, which showed a 61% tumor respon...
GSK announced that its experimental lung cancer drug, risvutatug rezetecan, achieved a 61% confirmed response rate at the higher 8 mg/kg dose in an early global trial involving patients with relapsed extensive-stage small cell lung cancer. This respo...
